C
메디톡스
086900KOSDAQ53.0 / 100
Reference Date: 2026-10-23
Financial Score18.5 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure15.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE falls significantly short of the industry average. Roughly flat over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Medytox specializes in the research, development, manufacturing, and sales of biopharmaceuticals using botulinum toxin type A, with flagship products such as Meditoxin® and Innotox®. In 2024, its key pharmaceutical products accounted for approximately 84% of consolidated revenue, and the company has expanded exports to over 30 countries.
Number of Employees
753people
Average Salary
64.4M KRW
Score Calculation Basis
Detailed Financial Score
PER
28.51Industry Average 15.001.5Point
1.9x industry avg (risky)
PBR
1.09Industry Average 1.204.0Point
In line with industry avg
ROE
3.39Industry Average 8.001.0Point
Well below industry avg
Debt Ratio
4.99Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20254.0 / 10 points
Revenue Growth Rate
2.0 / 3
Avg ▲5.8% (2-year basis)
Operating Profit Growth Rate
1.0 / 3
Avg ▲0.5% (2-year basis)
ROE Trend
1.0 / 4
Avg ROE 3.0% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (6%, downtrend)
Current 67,600Won52-week high 138,60052-week low 63,000
1-month return3.0Point
1m -0.88% (flat)
Volume trend3.0Point
Volume flat
Detailed Disclosure
4 totalPositive 3Neutral 1Negative 0
- Positive[기재정정]현금ㆍ현물배당결정2026-10-16
- Positive중간(분기)배당을위한주주명부폐쇄(기준일)결정2026-10-14
- Positive현금ㆍ현물배당결정2026-10-14
- Neutral[기재정정]주식소각결정 (상환전환우선주)2026-09-30